Sunshine Biopharma Signs Agreement with Lonza
News Nov 28, 2014
Sunshine Biopharma Inc. has announced an agreement with Lonza for the manufacture of its anti-cancer drug, Adva-27a. Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.
Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma. “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”